CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of chronic disease.
3.4.1.2. Rise in the adoption of precision medicine
3.4.1.3. Rise in technological advancement
3.4.2. Restraints
3.4.2.1. Lack of skilled professionals
3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Equipment
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunoassays
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chromatography-Spectrometry
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
6.1. Overview
6.1.1. Market size and forecast
6.2. Antiepileptic Drugs
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Antiarrhythmic Drugs
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Immunosuppressant Drugs
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Antibiotic Drugs
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: THERAPEUTIC DRUG MONITORING MARKET, BY END USERS
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Diagnostic labs
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Research and Academic Institutes
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: THERAPEUTIC DRUG MONITORING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Technology
8.2.4. Market size and forecast, by Drug Class
8.2.5. Market size and forecast, by End Users
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product
8.2.6.1.3. Market size and forecast, by Technology
8.2.6.1.4. Market size and forecast, by Drug Class
8.2.6.1.5. Market size and forecast, by End Users
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product
8.2.6.2.3. Market size and forecast, by Technology
8.2.6.2.4. Market size and forecast, by Drug Class
8.2.6.2.5. Market size and forecast, by End Users
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product
8.2.6.3.3. Market size and forecast, by Technology
8.2.6.3.4. Market size and forecast, by Drug Class
8.2.6.3.5. Market size and forecast, by End Users
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Technology
8.3.4. Market size and forecast, by Drug Class
8.3.5. Market size and forecast, by End Users
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product
8.3.6.1.3. Market size and forecast, by Technology
8.3.6.1.4. Market size and forecast, by Drug Class
8.3.6.1.5. Market size and forecast, by End Users
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product
8.3.6.2.3. Market size and forecast, by Technology
8.3.6.2.4. Market size and forecast, by Drug Class
8.3.6.2.5. Market size and forecast, by End Users
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product
8.3.6.3.3. Market size and forecast, by Technology
8.3.6.3.4. Market size and forecast, by Drug Class
8.3.6.3.5. Market size and forecast, by End Users
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product
8.3.6.4.3. Market size and forecast, by Technology
8.3.6.4.4. Market size and forecast, by Drug Class
8.3.6.4.5. Market size and forecast, by End Users
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product
8.3.6.5.3. Market size and forecast, by Technology
8.3.6.5.4. Market size and forecast, by Drug Class
8.3.6.5.5. Market size and forecast, by End Users
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product
8.3.6.6.3. Market size and forecast, by Technology
8.3.6.6.4. Market size and forecast, by Drug Class
8.3.6.6.5. Market size and forecast, by End Users
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Technology
8.4.4. Market size and forecast, by Drug Class
8.4.5. Market size and forecast, by End Users
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product
8.4.6.1.3. Market size and forecast, by Technology
8.4.6.1.4. Market size and forecast, by Drug Class
8.4.6.1.5. Market size and forecast, by End Users
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product
8.4.6.2.3. Market size and forecast, by Technology
8.4.6.2.4. Market size and forecast, by Drug Class
8.4.6.2.5. Market size and forecast, by End Users
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product
8.4.6.3.3. Market size and forecast, by Technology
8.4.6.3.4. Market size and forecast, by Drug Class
8.4.6.3.5. Market size and forecast, by End Users
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product
8.4.6.4.3. Market size and forecast, by Technology
8.4.6.4.4. Market size and forecast, by Drug Class
8.4.6.4.5. Market size and forecast, by End Users
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product
8.4.6.5.3. Market size and forecast, by Technology
8.4.6.5.4. Market size and forecast, by Drug Class
8.4.6.5.5. Market size and forecast, by End Users
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product
8.4.6.6.3. Market size and forecast, by Technology
8.4.6.6.4. Market size and forecast, by Drug Class
8.4.6.6.5. Market size and forecast, by End Users
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Technology
8.5.4. Market size and forecast, by Drug Class
8.5.5. Market size and forecast, by End Users
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product
8.5.6.1.3. Market size and forecast, by Technology
8.5.6.1.4. Market size and forecast, by Drug Class
8.5.6.1.5. Market size and forecast, by End Users
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product
8.5.6.2.3. Market size and forecast, by Technology
8.5.6.2.4. Market size and forecast, by Drug Class
8.5.6.2.5. Market size and forecast, by End Users
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product
8.5.6.3.3. Market size and forecast, by Technology
8.5.6.3.4. Market size and forecast, by Drug Class
8.5.6.3.5. Market size and forecast, by End Users
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product
8.5.6.4.3. Market size and forecast, by Technology
8.5.6.4.4. Market size and forecast, by Drug Class
8.5.6.4.5. Market size and forecast, by End Users
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Bio-Rad Laboratories, Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Siemens AG
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. F. Hoffmann-La Roche Ltd.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Abbott Laboratories
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Biomerieux SA
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Danaher Corporation
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Exagen Inc.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Thermo Fisher Scientific Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. SEKISUI CHEMICAL CO., LTD.
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Chromsystems Instruments & Chemicals GmbH
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
TABLE 01. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 02. THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
TABLE 03. THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY REGION, 2021-2031 ($MILLION)
TABLE 04. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 05. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY REGION, 2021-2031 ($MILLION)
TABLE 07. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 08. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 09. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 15. THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY REGION, 2021-2031 ($MILLION)
TABLE 16. THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($MILLION)
TABLE 18. THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 20. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 21. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 25. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 26. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 27. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 28. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 30. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 32. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 33. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 34. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 36. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 37. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 38. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 40. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 41. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 42. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 43. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 45. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 46. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 47. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 48. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 49. UK THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 50. UK THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 51. UK THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 52. UK THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 53. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 54. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 55. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 57. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 58. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 59. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 70. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 71. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 72. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 74. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 75. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 76. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 77. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 81. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 82. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 83. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 84. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 87. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 88. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 89. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 94. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 95. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 96. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 97. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 98. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 99. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 100. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 101. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 102. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 103. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 104. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 105. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 106. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 107. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 108. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 109. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 110. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 111. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 112. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
TABLE 113. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 114. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)
TABLE 115. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 116. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 117. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 118. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 119. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 120. SIEMENS AG: KEY EXECUTIVES
TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 128. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 129. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 130. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 131. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 132. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 133. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 134. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 135. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 136. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 137. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 138. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 139. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 140. EXAGEN INC.: KEY EXECUTIVES
TABLE 141. EXAGEN INC.: COMPANY SNAPSHOT
TABLE 142. EXAGEN INC.: PRODUCT SEGMENTS
TABLE 143. EXAGEN INC.: PRODUCT PORTFOLIO
TABLE 144. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 145. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 146. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 147. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 148. SEKISUI CHEMICAL CO., LTD.: KEY EXECUTIVES
TABLE 149. SEKISUI CHEMICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 150. SEKISUI CHEMICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 151. SEKISUI CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 152. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: KEY EXECUTIVES
TABLE 153. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY SNAPSHOT
TABLE 154. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT SEGMENTS
TABLE 155. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT PORTFOLIO
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
